Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.

HB 3717 establishes a Texas grant program to fund private entities conducting U.S. Food and Drug Administration (FDA) drug development trials using ibogaine. The program targets organizations (for-profit, nonprofit, or public benefit corporations) that can design and execute FDA trials to seek approval of ibogaine as a medication for treating opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions where ibogaine shows effectiveness. Applicants must submit detailed trial designs, team expertise, and FDA approval strategies. The grant covers costs for these trials, aiming to advance ibogaine's potential approval as a treatment option.